- Review of Phase 3 PL9643 Data for Dry Eye
Disease
- Data demonstrates PL9643 positive effects on
signs and symptoms of
dry eye disease
- Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET
CRANBURY, N.J., May 1, 2023
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American:
PTN), a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor system, today announced it will host a key
opinion leader (KOL) webinar on May 8,
2023 at 11:00 a.m. ET.
The webinar will be moderated by Carl
Spana, Ph.D., President & CEO of Palatin, and feature
Bruce C. Stouch, Ph.D. (Philadelphia College of Osteopathic Medicine) and
George Ousler, M.S. (Senior Vice
President of Anterior Segment, Ora). Dr. Stouch and Mr. Ousler will
present positive data from the PL9643 Phase 3 MELODY-1 trial
analysis of the Lead-In population which was recently presented at
the Association of Research in Vision and Ophthalmology 2023 Annual
Conference in New Orleans. The
PL9643 Melody-1 Phase 3 clinical study is continuing patient
enrollment, with final data expected in the second half of
2023.
Michael B. Raizman, M.D.,
practicing ophthalmologist and CMO of Palatin, will discuss the
unmet medical need and current treatment landscape for patients
suffering from dry eye disease (DED) and Palatin's potential
treatment solution with its PL9643 topical eye drops.
The KOL presentation will be followed by a question-and-answer
session with Dr. Stouch, Mr. Ousler, Dr. Raizman and Palatin senior
management. To register for the webinar and participate in the
webcast, please go to Palatin's website at www.palatin.com or click
here.
About Dry Eye Disease (DED)
Dry eye disease is a
common inflammatory disease that, left untreated, can become
extremely painful and lead to permanent damage to the cornea and
vision. DED affects the cornea and conjunctiva of the eye resulting
in irritation, redness, pain, and blurred vision. It is estimated
to affect over 20 million people in the
United States. The disease is characterized by insufficient
moisture and lubrication in the anterior surface of the eye,
leading to dryness, inflammation, pain, discomfort, irritation,
diminished quality of life, and in severe cases, permanent vision
impairment. Existing therapy for DED is generally regarded as
inadequate by many physicians and patients, and often requires
weeks or months to demonstrate activity.
About Melanocortin Receptor Agonists and
Inflammation
The melanocortin receptor ("MCr") system has
effects on inflammation, immune system responses, metabolism, food
intake, and sexual function. There are five melanocortin receptors,
MC1r through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects. Many tissues
and immune cells located throughout the body, including the gut,
kidney and eye, express melanocortin receptors, empowering our
opportunity to directly activate natural pathways to resolve
disease inflammation. Drugs based on melanocortin agonists have
been approved by the FDA for treating several conditions, including
female sexual dysfunction, inflammatory/autoimmune diseases, and
rare forms of genetic obesity.
About Palatin
Palatin is a biopharmaceutical
company developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and
commercial potential. Palatin's strategy
is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com and follow
Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this
press release that are not historical facts, including statements
about future expectations of Palatin, such as statements about
PL9643 clinical results, are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and as that
term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject to the
safe harbors created thereby. Such forward-looking statements
involve known and unknown risks, uncertainties and other
factors that could cause Palatin's actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating events that
occur after the date of this press release.
Palatin Technologies® is a registered trademark of
Palatin Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-technologies-to-host-key-opinion-leader-webinar-301812297.html
SOURCE Palatin Technologies, Inc.